Literature DB >> 17531271

C-reactive protein: a pentraxin with anti-acetylcholine activity.

Peter G Nazarov1, Irina B Krylova, Natalia R Evdokimova, Galina I Nezhinskaya, Alexander A Butyugov.   

Abstract

Purified C-reactive protein (CRP) diminished effects of acetylcholine (ACh) on the vascular tone and the heart rate of rats in vivo. In vitro CRP inhibited breakdown of ACh by acetylcholinesterase (AChE) while did not interact with AChE itself. CRP appears to bind ACh. CRP did not modify the cardiovascular effects of adenosine, another vasorelaxant. The data suggest that there is a new line of cross-talk between the inflammation and cholinergic regulation with CRP acting on endothelium via the ACh-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531271     DOI: 10.1016/j.lfs.2007.04.031

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Mini Review: Anticholinergic Activity as a Behavioral Pathology of Lewy Body Disease and Proposal of the Concept of "Anticholinergic Spectrum Disorders".

Authors:  Koji Hori; Kimiko Konishi; Misa Hosoi; Hiroi Tomioka; Masayuki Tani; Yuka Kitajima; Mitsugu Hachisu
Journal:  Parkinsons Dis       Date:  2016-09-22

2.  Acetylcholine Inhibits Monomeric C-Reactive Protein Induced Inflammation, Endothelial Cell Adhesion, and Platelet Aggregation; A Potential Therapeutic?

Authors:  Mark Slevin; Rocco S Iemma; Yasmin Zeinolabediny; Donghui Liu; Glenn R Ferris; Vittorio Caprio; Nicola Phillips; Mario Di Napoli; Baoqiang Guo; Xianwei Zeng; Raid AlBaradie; Naif K Binsaleh; Garry McDowell; Wen-Hui Fang
Journal:  Front Immunol       Date:  2018-09-26       Impact factor: 7.561

Review 3.  Negative regulation of ATP-induced inflammasome activation and cytokine secretion by acute-phase proteins: A mini review.

Authors:  Katrin Richter; Anca-Laura Amati; Winfried Padberg; Veronika Grau
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

4.  Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.

Authors:  Carol Milligan; Nazem Atassi; Suma Babu; Richard J Barohn; James B Caress; Merit E Cudkowicz; Armineuza Evora; Gregory A Hawkins; Marlena Wosiski-Kuhn; Eric A Macklin; Jeremy M Shefner; Zachary Simmons; Robert P Bowser; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2021-06-24       Impact factor: 3.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.